Browsing ICR Divisions by author "Williamson, Andrew"
Now showing items 1-1 of 1
-
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai, X; Shaheen, A; Grieco, C; d'Arienzo, PD; Mina, F; et al. (ELSEVIER, 2023-11-01)BACKGROUND: Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative ...